{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:47:00Z","timestamp":1794412020623,"version":"4.9.0"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.biopha.2025.117858","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T22:56:22Z","timestamp":1739660182000},"page":"117858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy"],"prefix":"10.1016","volume":"184","author":[{"given":"Mohsen","family":"Sheykhhasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Ahmadieh-Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Chamanara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Poondla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Malih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Manoochehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Tanzadehpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanie","family":"Mahaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashmin","family":"Fayazi Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Dirbaziyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharafaldin","family":"Al-Musawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Kalhor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","article-title":"Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study","volume":"29","author":"Sheykhhasan","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13402-021-00593-1","article-title":"CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities","volume":"44","author":"Akhoundi","year":"2021","journal-title":"Cell. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2325","article-title":"Therapeutic roles of CAR T cells in infectious diseases: clinical lessons learnt from cancer","volume":"32","author":"Mohammadi","year":"2022","journal-title":"Rev. Med. Virol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32249","article-title":"Pro-inflammatory responses after peptide-based cancer immunotherapy","volume":"10","author":"Mahaki","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2025.117858_bib6","series-title":"Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy","author":"Sahlolbei","year":"2024"},{"key":"10.1016\/j.biopha.2025.117858_bib7","first-page":"33","article-title":"Advancement in \u201coff-the-shelf\u201d CAR T-cell therapy for cancer immunotherapy","author":"Sheykhhassan","year":"2024","journal-title":"Crit. Dev. Cancer Immunother."},{"key":"10.1016\/j.biopha.2025.117858_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med"},{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib10","article-title":"Extracellular Vesicles in Cancer Immunotherapy: Therapeutic, Challenges, and Clinical Progress","author":"Manoochehri","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/1574888X17666220217101817","article-title":"The promise of CAR T-cell therapy for the treatment of cancer stem cells: a short review","volume":"17","author":"Poondla","year":"2022","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1574888X17666220401102718","article-title":"Dendritic cells - winning the fight against HIV","volume":"18","author":"Poondla","year":"2023","journal-title":"Curr. stem Cell Res. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8040706","article-title":"DC-based vaccines for cancer immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2025.117858_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.730824","article-title":"Recent advances in experimental dendritic cell vaccines for cancer","volume":"11","author":"Filin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.117858_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib16","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.117858_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114954","article-title":"Advances in dendritic cell vaccination therapy of cancer","volume":"164","author":"Najafi","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin Oncol."},{"key":"10.1016\/j.biopha.2025.117858_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S29834","article-title":"Cancer as an immune-mediated disease","volume":"1","author":"Shurin","year":"2012","journal-title":"Immunotargets Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050535","article-title":"Evolution of cancer vaccines-challenges, achievements, and future directions","volume":"9","author":"Tay","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2025.117858_bib21","series-title":"Ralph M. Steinman","first-page":"1943","article-title":"The fabulous legacy of a Nobel Prize Laureate","author":"Zitvogel","year":"2012"},{"key":"10.1016\/j.biopha.2025.117858_bib22","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2096363","article-title":"Trial watch: dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2025.117858_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark. Res"},{"key":"10.1016\/j.biopha.2025.117858_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.00113","article-title":"Neutrophil: a cell with many roles in inflammation or several cell types?","volume":"9","author":"Rosales","year":"2018","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8040737","article-title":"DNA vaccine development at pre- and post-operation warp speed","volume":"8","author":"Ljungberg","year":"2020","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030590","article-title":"Dendritic cells in anticancer vaccination: rationale for ex vivo loading or in vivo targeting","volume":"12","author":"Baldin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.117858_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fimmu.2013.00138","article-title":"The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity","volume":"4","author":"Gallo","year":"2013","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib29","doi-asserted-by":"crossref","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw."},{"key":"10.1016\/j.biopha.2025.117858_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841687","article-title":"New insights of CCR7 signaling in dendritic cell migration and inflammatory diseases","volume":"13","author":"Hong","year":"2022","journal-title":"Front Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41577-018-0088-1","article-title":"Dendritic cell subsets in T cell programming: location dictates function","volume":"19","author":"Eisenbarth","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.biopha.2025.117858_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212339","article-title":"Dendritic cells and cancer immunotherapy: the adjuvant effect","volume":"22","author":"Nava","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.117858_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112918","article-title":"Poly(I:C) induces antiviral immune responses in Japanese flounder (Paralichthys olivaceus) that require TLR3 and MDA5 and is negatively regulated by Myd88","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1513\/pats.200701-021AW","article-title":"Antiinfective applications of toll-like receptor 9 agonists","volume":"4","author":"Krieg","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib36","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2025.117858_bib37","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3389\/fphar.2019.01152","article-title":"Immunotherapy based on dendritic cell-targeted\/-derived extracellular vesicles-a novel strategy for enhancement of the anti-tumor immune response","volume":"10","author":"Markov","year":"2019","journal-title":"Front Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib39","first-page":"108","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis","volume":"8","author":"Wise","year":"2018","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.biopha.2025.117858_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells","volume":"13","author":"S\u00e1nchez-Le\u00f3n","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","article-title":"Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer","volume":"9","author":"Versteven","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010108","article-title":"Cancer immunotherapy: silencing intracellular negative immune regulators of dendritic cells","volume":"11","author":"Liu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.117858_bib43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3389\/fimmu.2018.00982","article-title":"Strategies to genetically modulate dendritic cells to potentiate anti-tumor responses in hematologic malignancies","volume":"9","author":"Cornel","year":"2018","journal-title":"Front Immunol."},{"issue":"19","key":"10.1016\/j.biopha.2025.117858_bib44","first-page":"11397","article-title":"Plasmacytoid Dendritic Cells as a Novel Cell-Based Cancer","volume":"23","author":"Hern\u00e1ndez","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2025.117858_bib45","series-title":"Methods and Protocols","first-page":"477","article-title":"In Vitro Generation of Human Tolerogenic Monocyte-Derived Dendritic Cells","author":"Hilkens","year":"2023"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2025.117858_bib47","doi-asserted-by":"crossref","first-page":"24947","DOI":"10.1021\/acsnano.3c06784","article-title":"Dendritic cell-based in situ nanovaccine for reprogramming lipid metabolism to boost tumor immunotherapy","volume":"17","author":"Qin","year":"2023","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113138","article-title":"Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy","volume":"42","author":"Xu","year":"2023","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111756","article-title":"Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer","volume":"11","author":"Marhelava","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.117858_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt.09.43","article-title":"Directing dendritic cell immunotherapy towards successful cancer treatment","volume":"2","author":"Sabado","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2025.117858_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110365","article-title":"Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis","volume":"146","author":"Saadeldin","year":"2021","journal-title":"Med Hypotheses"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol. Rev."},{"issue":"232","key":"10.1016\/j.biopha.2025.117858_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008068","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","author":"Dhodapkar","year":"2014","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13020142","article-title":"TLR agonists as vaccine adjuvants targeting cancer and infectious diseases","volume":"13","author":"Luchner","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.117858_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.674048","article-title":"Therapeutic liposomal vaccines for dendritic cell activation or tolerance","volume":"12","author":"Nagy","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib57","article-title":"Cationic lipids-mediated dual-targeting of both dendritic cells and tumor cells for potent cancer immunotherapy","author":"Li","year":"2023","journal-title":"Adv. Funct. Mater."},{"issue":"23","key":"10.1016\/j.biopha.2025.117858_bib58","doi-asserted-by":"crossref","first-page":"15130","DOI":"10.3390\/ijms232315130","article-title":"Breast cancer vaccine containing a novel toll-like receptor 7 agonist and an aluminum adjuvant exerts antitumor effects","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell-based cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib60","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib61","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.4161\/21645515.2014.982996","article-title":"Tumor cell lysates as immunogenic sources for cancer vaccine design","volume":"10","author":"Gonz\u00e1lez","year":"2014","journal-title":"Hum. Vaccin Immunother."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib62","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/sj.cgt.7700509","article-title":"MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells","volume":"9","author":"Sloan","year":"2002","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib63","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1560919","article-title":"Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells","volume":"8","author":"Rabu","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1_ement","key":"10.1016\/j.biopha.2025.117858_bib65","doi-asserted-by":"crossref","first-page":"159.10","DOI":"10.4049\/jimmunol.210.Supp.159.10","article-title":"Peptide-pulsed MHC class II mutant dendritic cell vaccine has superior efficacy in a murine tumor model","volume":"210","author":"Seishima","year":"2023","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8040776","article-title":"Neo-antigen mRNA vaccines","volume":"8","author":"Esprit","year":"2020","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.biopha.2025.117858_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1207842","article-title":"mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma","volume":"5","author":"Borch","year":"2016","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib68","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193220","article-title":"Engineering anti-cancer nanovaccine based on antigen cross-presentation","volume":"39","author":"Warrier","year":"2019","journal-title":"Biosci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8040615","article-title":"Selecting target antigens for cancer vaccine development","volume":"8","author":"Buonaguro","year":"2020","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib70","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","article-title":"Update on tumor neoantigens and their utility: why it is good to be different","volume":"39","author":"Lee","year":"2018","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.coi.2008.04.011","article-title":"Peptide epitope identification for tumor-reactive CD4 T cells","volume":"20","author":"Kobayashi","year":"2008","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib72","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/94.11.805","article-title":"Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?","volume":"94","author":"Parmiani","year":"2002","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"19","key":"10.1016\/j.biopha.2025.117858_bib73","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.3390\/cancers16193254","article-title":"Short peptides as powerful arsenal for smart fighting cancer","volume":"16","author":"Bojarska","year":"2024","journal-title":"Cancers"},{"issue":"9-10","key":"10.1016\/j.biopha.2025.117858_bib74","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: principles, progress and prospects","volume":"18","author":"Leitner","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/vaccines12020152","article-title":"Can the revolution in mRNA-based vaccine technologies solve the intractable health issues of current ruminant production systems?","volume":"12","author":"Mahony","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2025.117858_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.11.001","article-title":"Peptide vaccines in cancer-old concept revisited","volume":"45","author":"Kumai","year":"2017","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib77","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acsabm.1c01238","article-title":"Peptides for vaccine development","volume":"5","author":"Hamley","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"issue":"16","key":"10.1016\/j.biopha.2025.117858_bib79","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2025.117858_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696791","article-title":"Beyond just peptide antigens: the complex world of peptide-based cancer vaccines","volume":"12","author":"Stephens","year":"2021","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093231","article-title":"Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response","volume":"9","author":"Kissick","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib83","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/pathogens13060500","article-title":"Brief insights into mRNA vaccines: their successful production and nanoformulation for effective response against COVID-19 and their potential success for influenza A and B","volume":"13","author":"Parveen","year":"2024","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib84","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acsabm.1c01238","article-title":"Peptides for vaccine development","volume":"5","author":"Hamley","year":"2022","journal-title":"ACS Appl. Bio Mater."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib85","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib86","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41423-020-0465-0","article-title":"Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses","volume":"17","author":"Hilligan","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib87","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fimmu.2013.00438","article-title":"Immature, semi-mature, and fully mature dendritic cells: toward a dc-cancer cells interface that augments anticancer immunity","volume":"4","author":"Dudek","year":"2013","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031445","article-title":"Bioactive peptides: synthesis, sources, applications, and proposed mechanisms of action","volume":"23","author":"Akbarian","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib89","first-page":"2091","article-title":"Dendritic cells based immunotherapy","volume":"7","author":"Shang","year":"2017","journal-title":"Am. J. Cancer Res"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib90","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2217\/imt.10.56","article-title":"Enhancement of dendritic cells as vaccines for cancer","volume":"2","author":"Turnis","year":"2010","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib91","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1089\/lrb.2013.0008","article-title":"Dendritic cell interactions with lymphatic endothelium","volume":"11","author":"Russo","year":"2013","journal-title":"Lymphat Res Biol."},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102438","article-title":"Lymph nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy","volume":"14","author":"Morisaki","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib93","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1019197","article-title":"Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients","volume":"4","author":"Bol","year":"2015","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib94","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41423-018-0005-3","article-title":"Chemokine and chemotactic signals in dendritic cell migration","volume":"15","author":"Tiberio","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib95","first-page":"663","article-title":"Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines","volume":"6","author":"Vandenberk","year":"2015","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib96","article-title":"Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/jsre.2000.6075","article-title":"Comparison of intradermal and subcutaneous injections in lymphatic mapping","volume":"96","author":"Kersey","year":"2001","journal-title":"J. Surg. Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib98","first-page":"366","article-title":"Comparison of intraparenchymal and intradermal injection for identification of the sentinel node in patients with breast cancer","volume":"15","author":"Knox","year":"2002","journal-title":"Proc. (Bayl. Univ. Med Cent."},{"key":"10.1016\/j.biopha.2025.117858_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.immuni.2006.03.014","article-title":"Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization","volume":"24","author":"He","year":"2006","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib101","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.117858_bib102","article-title":"Crosstalk between the tumor microenvironment and cancer cells: a promising predictive biomarker for immune checkpoint inhibitors","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"18","key":"10.1016\/j.biopha.2025.117858_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-directed tumor microenvironment modulation in cancer immunotherapy","volume":"22","author":"Bule","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.117858_bib104","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3389\/fimmu.2019.02393","article-title":"Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications","volume":"10","author":"Fucikova","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib105","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3332\/ecancer.2020.1148","article-title":"Combinations using checkpoint blockade to overcome resistance","volume":"14","author":"Morganti","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib106","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3324\/haematol.2020.259457","article-title":"Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model","volume":"106","author":"Stroopinsky","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2025.117858_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1155377","article-title":"Combined therapy with methotrexate nanoconjugate and dendritic cells with downregulated IL-10R expression modulates the tumor microenvironment and enhances the systemic anti-tumor immune response in MC38 murine colon carcinoma","volume":"14","author":"Szczygie\u0142","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib108","first-page":"1897","article-title":"A new plasmacytoid dendritic cell-based vaccine in combination with anti-PD-1 expands the tumor-specific CD8+\u2009T cells of lung cancer patients","volume":"24","author":"Hannani","year":"2023"},{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib109","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00262-021-03129-6","article-title":"Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells","volume":"71","author":"Liao","year":"2022","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.biopha.2025.117858_bib110","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jconrel.2024.07.050","article-title":"Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1 magnetic resonance imaging","volume":"373","author":"Hou","year":"2024","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib111","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00262-022-03283-5","article-title":"A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study","volume":"72","author":"Espa\u00f1ol-Rego","year":"2023","journal-title":"Cancer Immunol., Immunother.: CII"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41698-022-00279-3","article-title":"Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer","volume":"6","author":"Guo","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.biopha.2025.117858_bib113","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib115","first-page":"460","article-title":"\u03b2-catenin in dendritic cells negatively regulates CD8 T cell immune responses through the immune checkpoint molecule tim-3","volume":"12","author":"Fu","year":"2024"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib116","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.biopha.2025.117858_bib117","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-023-03525-0","article-title":"Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma","author":"Chang","year":"2023","journal-title":"Cancer Immunol., Immunother."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib118","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8(+) T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib119","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"16_","key":"10.1016\/j.biopha.2025.117858_bib120","article-title":"Activation of dendritic cells by a synthesized small molecule for breast cancer vaccination","volume":"42","author":"Wu","year":"2024","journal-title":"e"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2025.117858_bib122","article-title":"Aducanumab therapy to treat Alzheimer's disease: a narrative review","volume":"2022","author":"Beshir","year":"2022","journal-title":"Int J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.117858_bib123","article-title":"Laponite lights calcium flickers by reprogramming lysosomes to steer Dc migration for an effective antiviral CD8+\u2009T-cell response","author":"Li","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biopha.2025.117858_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1154818","article-title":"Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer","volume":"14","author":"Tong","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib125","first-page":"45","article-title":"NKT-licensed in vivo dendritic cell\u2212based immunotherapy as cellular immunodrugs for cancer treatment","volume":"29","author":"Fujii","year":"2024"},{"key":"10.1016\/j.biopha.2025.117858_bib126","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.669965","article-title":"Autologous dendritic cells in combination with chemotherapy restore responsiveness of T cells in breast cancer patients: a single-arm phase I\/II trial","volume":"12","author":"Bernal-Est\u00e9vez","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007070","article-title":"Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial","volume":"11","author":"Dietz","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib128","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.biopha.2025.117858_bib129","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/gt.2015.43","article-title":"Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma","volume":"22","author":"Sundarasetty","year":"2015","journal-title":"Gene Ther."},{"issue":"6415","key":"10.1016\/j.biopha.2025.117858_bib130","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1126\/science.aat5030","article-title":"WDFY4 is required for cross-presentation in response to viral and tumor antigens","volume":"362","author":"Theisen","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.gt.3302358","article-title":"Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction","volume":"12","author":"Okada","year":"2005","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib132","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CJI.0b013e3181a28422","article-title":"Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma","volume":"32","author":"Knippertz","year":"2009","journal-title":"J. Immunother."},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib133","first-page":"451","article-title":"Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery","volume":"26","author":"Koya","year":"2003"},{"issue":"22","key":"10.1016\/j.biopha.2025.117858_bib134","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-04-278739","article-title":"siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells","volume":"116","author":"Hobo","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","article-title":"Towards superior dendritic-cell vaccines for cancer therapy","volume":"2","author":"Saxena","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biopha.2025.117858_bib136","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65856","article-title":"CRISPR-based functional genomics in human dendritic cells","volume":"10","author":"Jost","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.biopha.2025.117858_bib137","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65856","article-title":"CRISPR-based functional genomics in human dendritic cells","volume":"10","author":"Jost","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.biopha.2025.117858_bib138","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.2147\/IJN.S424872","article-title":"Innovative strategies of reprogramming immune system cells by targeting CRISPR\/Cas9-based genome-editing tools: a new era of cancer management","volume":"18","author":"Allemailem","year":"2023","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib139","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.cell.2023.02.031","article-title":"Delivering the next generation of cancer immunotherapies with RNA","volume":"186","author":"Raimondo","year":"2023","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.biopha.2025.117858_bib140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mrna electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.117858_bib141","first-page":"1330","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib142","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib143","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103(+) dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib144","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9101060","article-title":"mRNA-based cancer vaccines: a therapeutic strategy for the treatment of melanoma patients","volume":"9","author":"Bidram","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2025.117858_bib146","doi-asserted-by":"crossref","unstructured":"Das R., Ge X., Fei F., Parvanian S., Weissleder R., Garris C.S. Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response.n\/a(n\/a):2400633. doi: https:\/\/doi.org\/10.1002\/smtd.202400633.","DOI":"10.1002\/smtd.202400633"},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib147","first-page":"5997","article-title":"The improved antigen uptake and presentation of dendritic cells using cell-penetrating D-octaarginine-linked PNVA-co-AA as a novel dendritic cell-based vaccine","volume":"25","author":"Fujioka","year":"2024"},{"key":"10.1016\/j.biopha.2025.117858_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119302","article-title":"In situ repurposing of dendritic cells with CRISPR\/Cas9-based nanomedicine to induce transplant tolerance","volume":"217","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib149","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.cell.2011.11.021","article-title":"Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells","volume":"147","author":"Cebrian","year":"2011","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/ni.3196","article-title":"The transcription factor TFEB acts as a molecular switch that regulates exogenous antigen-presentation pathways","volume":"16","author":"Samie","year":"2015","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib151","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nmeth.4579","article-title":"EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens","volume":"15","author":"Squadrito","year":"2018","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.biopha.2025.117858_bib152","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.celrep.2018.05.068","article-title":"Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells","volume":"23","author":"Kirkling","year":"2018","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib153","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.celrep.2018.07.033","article-title":"Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity","volume":"24","author":"Balan","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib154","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib155","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1084\/jem.20061800","article-title":"Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade","volume":"203","author":"Freeman","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2025.117858_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121138","article-title":"The impact of microbiota on PD-1\/PD-L1 inhibitor therapy outcomes: a focus on solid tumors","volume":"310","author":"Najafi","year":"2022","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.117858_bib157","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23403","article-title":"Cancer vaccines: looking to the future","volume":"2","author":"Yaddanapudi","year":"2013","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib158","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/14760584.3.4.349","article-title":"Vaccines for neonatal viral infections: hepatitis B vaccine","volume":"3","author":"Cutts","year":"2004","journal-title":"Expert Rev. Vaccin."},{"issue":"12 2","key":"10.1016\/j.biopha.2025.117858_bib159","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human papillomavirus vaccines","volume":"224","author":"Markowitz","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines - a review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib161","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1002\/eji.200737820","article-title":"Prevention of cancer through immunization: prospects and challenges for the 21st century","volume":"37","author":"Frazer","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib162","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib163","first-page":"1345","article-title":"Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer","volume":"66","author":"Sonpavde","year":"2017"},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib164","article-title":"Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma","volume":"6","author":"Dillman","year":"2019"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib165","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib166","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-018-2198-9","article-title":"A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia","volume":"67","author":"van de Loosdrecht","year":"2018","journal-title":"Cancer Immunol. Immunother.: CII"},{"key":"10.1016\/j.biopha.2025.117858_bib167","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-3987","article-title":"Survivin dendritic cell vaccine safely induces immune responses and is associated with durable disease control after autologous transplant in patients with myeloma","author":"Freeman","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib168","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.117858_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","author":"Zhu","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib170","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1007\/s00262-023-03482-8","article-title":"Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma","volume":"72","author":"Takei","year":"2023","journal-title":"Cancer Immunol., Immunother."},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib171","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib172","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib173","first-page":"197","article-title":"Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer","volume":"36","author":"Anassi","year":"2011","journal-title":"P t"},{"key":"10.1016\/j.biopha.2025.117858_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.770390","article-title":"Dendritic cell vaccination of glioblastoma: road to success or dead end","volume":"12","author":"Datsi","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/cns.14.54","article-title":"Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax\u00ae platform in the treatment of glioblastoma multiforme","volume":"4","author":"Hdeib","year":"2015","journal-title":"CNS Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib176","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638212","article-title":"Trial watch: dendritic cell vaccination for cancer immunotherapy","volume":"8","author":"Sprooten","year":"2019","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.biopha.2025.117858_bib177","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2019-0086","article-title":"Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN(\u00ae) in combination with chemotherapy","volume":"5","author":"Kumar","year":"2019","journal-title":"Future Sci. OA"},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib178","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","article-title":"Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma","volume":"10","author":"Peng","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib179","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2220629","article-title":"A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma","volume":"19","author":"DeBenedette","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"9","key":"10.1016\/j.biopha.2025.117858_bib180","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","article-title":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","volume":"37","author":"Fl\u00f8isand","year":"2023","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.biopha.2025.117858_bib181","first-page":"3083","article-title":"Dendritic cell\u2013based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"Land FRvt","year":"2024"},{"key":"10.1016\/j.biopha.2025.117858_bib182","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211034708","article-title":"New approaches to first-line treatment of advanced renal cell carcinoma","volume":"13","author":"George","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117858_bib183","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2220629","article-title":"A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma","volume":"19","author":"DeBenedette","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib184","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010463","article-title":"Dendritic cell-triggered immune activation goes along with provision of (leukemia-specific) integrin beta 7-expressing immune cells and improved antileukemic processes","volume":"24","author":"Rackl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib185","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10071092","article-title":"A novel therapeutic tumor vaccine targeting MUC1 in combination with PD-L1 elicits specific anti-tumor immunity in mice","volume":"10","author":"Pan","year":"2022","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib186","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002620050590","article-title":"How tumors escape immune destruction and what we can do about it","volume":"48","author":"Gilboa","year":"1999","journal-title":"Cancer Immunol. Immunother.: CII"},{"key":"10.1016\/j.biopha.2025.117858_bib187","series-title":"In: Rezaei N, Keshavarz-Fathi M, editors. Vaccines for Cancer Immunotherapy","first-page":"117","article-title":"Chapter 9 - Immune Cell Vaccine for Cancer","author":"Razi","year":"2019"},{"issue":"8","key":"10.1016\/j.biopha.2025.117858_bib188","first-page":"744","article-title":"Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy","volume":"20","author":"Yoshimura","year":"2013","journal-title":"Int. J. Urol. Off. J. Jpn. Urol. Assoc."},{"issue":"6","key":"10.1016\/j.biopha.2025.117858_bib189","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/fon.16.13","article-title":"Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20\/eltrapuldencel-T)","volume":"12","author":"Javed","year":"2016","journal-title":"Future Oncol. (Lond., Engl. )"},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1749-0774.2003.tb00151.x","article-title":"Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives","volume":"16","author":"Morisaki","year":"2003","journal-title":"Hum. Cell"},{"issue":"13","key":"10.1016\/j.biopha.2025.117858_bib191","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137325","article-title":"Dendritic cell-based immunotherapy in hot and cold tumors","volume":"23","author":"Kang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.117858_bib192","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/emboj\/cdg261","article-title":"Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity","volume":"22","author":"Zanoni","year":"2003","journal-title":"EMBO J."},{"issue":"436","key":"10.1016\/j.biopha.2025.117858_bib193","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2025.117858_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114954","article-title":"Advances in dendritic cell vaccination therapy of cancer","volume":"164","author":"Najafi","year":"2023","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.117858_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.117858_bib196","article-title":"Dendritic cells: the yin and yang in disease progression","volume":"14","author":"Jim\u00e9nez-Cortegana","year":"2023","journal-title":"Front Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2025.117858_bib197","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172147","article-title":"Dendritic cell vaccines: a shift from conventional approach to new generations","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib198","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.117858_bib199","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/cr.2016.157","article-title":"Dendritic cell-based immunotherapy","volume":"27","author":"Sabado","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2025.117858_bib200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030590","article-title":"Dendritic cells in anticancer vaccination: rationale for ex vivo loading or in vivo targeting","author":"Baldin","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.117858_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.686544","article-title":"Insights into dendritic cells in cancer immunotherapy: from bench to clinical applications","volume":"9","author":"Salah","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.117858_bib202","unstructured":"Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. (1097-4180 (Electronic))."},{"key":"10.1016\/j.biopha.2025.117858_bib203","doi-asserted-by":"crossref","unstructured":"Calmeiro J., Carrascal M.A., Tavares A.R., Ferreira D.A., Gomes C., Falc\u00e3o A., et al. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics. 2020 doi: 10.3390\/pharmaceutics12020158.","DOI":"10.3390\/pharmaceutics12020158"},{"issue":"5","key":"10.1016\/j.biopha.2025.117858_bib204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.biopha.2025.117858_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172147","article-title":"Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations","author":"Lee","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.117858_bib206","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9111363","article-title":"The advantages and challenges of anticancer dendritic cell vaccines and NK cells in adoptive cell immunotherapy","author":"Abakushina","year":"2021","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.biopha.2025.117858_bib207","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.biopha.2025.117858_bib208","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells","volume":"13","author":"S\u00e1nchez-Le\u00f3n","year":"2022","journal-title":"Front. Immunol."},{"issue":"6236","key":"10.1016\/j.biopha.2025.117858_bib209","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib210","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201903301","article-title":"Artificial mini dendritic cells boost T cell\u2013based immunotherapy for ovarian cancer","volume":"7","author":"Cheng","year":"2020","journal-title":"Adv. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.117858_bib211","article-title":"Trial watch: dendritic cell-based anticancer immunotherapy","volume":"6","author":"Garg","year":"2017","journal-title":"OncoImmunology"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:44:01Z","timestamp":1741027441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":211,"alternative-id":["S0753332225000526"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117858","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117858"}}